{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:37:43Z","timestamp":1783456663464,"version":"3.55.0"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,9,20]],"date-time":"2012-09-20T00:00:00Z","timestamp":1348099200000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to investigate the effect of dose and other factors on plasma amisulpride concentrations in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Amisulpride therapeutic drug monitoring data 2002\u20132010 have been studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 296 samples (196 adult patients). Amisulpride was not detected in 10% of samples. In the remainder, the mean plasma amisulpride in relation to the prescribed dose (mg\/day) was as follows: 100\u2013200 (111\u2009\u00b5g\/L), 201\u2013400 (254\u2009\u00b5g\/L), 400\u2013800 (421\u2009\u00b5g\/L), and 800\u20131200 (494\u2009\u00b5g\/L). For prescribed doses up to 800\u2009mg\/day, only 51% of results were within 100\u2013319\u2009\u00b5g\/L. There were no significant sex differences in mean plasma amisulpride or mean dose. The mean plasma amisulpride, but not the dose, was significantly higher in smokers. Linear regression analysis showed that dose explained only 42% of the variation in plasma amisulpride after log<jats:sub>10<\/jats:sub> transformation of both variables. There was no significant difference in the mean dose or mean plasma amisulpride in patients co\u2010prescribed clozapine as compared with the remaining samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In practice, dose is a poor predictor of plasma amisulpride concentration. Therapeutic drug monitoring may not only help assess adherence, but also guide dosage. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2256","type":"journal-article","created":{"date-parts":[[2012,9,20]],"date-time":"2012-09-20T09:56:44Z","timestamp":1348135004000},"page":"507-513","source":"Crossref","is-referenced-by-count":19,"title":["Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002\u20132010"],"prefix":"10.1002","volume":"27","author":[{"given":"Sally V. J.","family":"Bowskill","sequence":"first","affiliation":[{"name":"Toxicology Unit, Department of Clinical Biochemistry King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine X.","family":"Patel","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Department of Psychosis Studies King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Handley","sequence":"additional","affiliation":[{"name":"Toxicology Unit, Department of Clinical Biochemistry King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Toxicology Unit, Department of Clinical Biochemistry King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-993209"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110391123"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2003.09.001"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31814f4dbb"},{"key":"e_1_2_7_6_1","volume-title":"British National Formulary","author":"BMJ Group and Pharmaceutical Press","year":"2011"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.8.1413"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1826-6"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038050-00002"},{"key":"e_1_2_7_10_1","unstructured":"Clinical and Laboratory Standards Institute.2004.Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline. Edition 2. Document EP05\u2010A 2 (http:\/\/webstore.ansi.org\/RecordDetail.aspx?sku=CLSI+EP05\u2010A2 accessed 4 April 2012)."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181dad1fb"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2165\/00023210-199606030-00006","article-title":"Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia","volume":"6","author":"Coukell AJ","year":"1996","journal-title":"CNS Drugs"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800250087012"},{"key":"e_1_2_7_14_1","unstructured":"FDA\/CDER (Food and Drug Administration\/Center for Drug Evaluation and Research).2001.Guidance for industry. Bioanalytical method validation. (http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070107.pdf accessed 4 April 2012)."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199705002-00004"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02849987"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2009.04.003"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050483"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286287"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.4.514"},{"key":"e_1_2_7_21_1","first-page":"1028","article-title":"D2 receptor occupancy during high\u2010 and low\u2010dose therapy with the atypical antipsychotic amisulpride: a 123I\u2010iodobenzamide SPECT study","volume":"46","author":"La Foug\u00e8re C","year":"2005","journal-title":"J Nucl Med"},{"key":"e_1_2_7_22_1","volume-title":"Clarke's Analysis of Drugs and Poisons","author":"Moffat AC","year":"2011"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.55"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-931540"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2005.10.003"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108089806"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2004.00356.x"},{"key":"e_1_2_7_28_1","unstructured":"National Institute for Health and Clinical Excellence.2009.Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE Clinical Guideline 82 (http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG82NICEGuideline.pdf accessed 26 October 2011)."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2010.00222.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318221b408"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1998.tb10044.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.320"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbr004"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2009.01429.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145704004353"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2256","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:20:21Z","timestamp":1695471621000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1002\/hup.2256"],"URL":"https:\/\/doi.org\/10.1002\/hup.2256","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}